Thalidomide and Dexamethasone Induction Therapy Until Best Response in Recently Diagnosed Patients with Multiple Myeloma: Results From a Pilot Study.
Novel therapies for multiple myeloma are not affordable for all healthcare systems. The objectives of this study were to evaluate the response rates, overall survival, event-free survival, and toxicity of thalidomide and dexamethasone administered until best response in recently diagnosed patients with multiple myeloma. All recently diagnosed multiple myeloma patients meeting the inclusion criteria received the same treatment with thalidomide and dexamethasone. We studied 28 patients. Overall response rate was 75%. Complete response, partial response, and very good partial response were 25.0, 32.1, and 17.9%, respectively. The most frequent adverse event related to therapy was neuropathy. Median overall survival was 66 months, and median event-free survival was 39 months (range, 27.6-50.4). Variables that negatively affected overall survival on multivariate analysis included the presence of extramedullary disease, t(14;16), and chromosome 13 deletion. Induction therapy with thalidomide and dexamethasone until obtaining the best response in patients with recently diagnosed multiple myeloma was a useful and safe strategy. It represents an alternative for patients with limited access to costly drugs.